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The P2X7 receptor is a membrane bound cation channel expressed mainly on the surface 
of immune cells such as macrophages, lymphocytes and dendritic cells. P2X7 receptor 
expression is up-regulated in response to the cytokine, IFN-, which also plays an 
integral role in the immune response to Toxoplasma gondii. Activation of the P2X7 
receptor is achieved through prolonged exposure to > 100M ATP, which may be 
released from a variety of cellular sources, including activated platelets and 
dead/dying/damaged cells (including cellular damage caused by intracellular 
pathogens). Various studies have already demonstrated the ability of P2X7 receptor 
activation to kill intracellular Mycobacterium spp., and have also linked a defective 
P2X7 receptor with tuberculosis in humans. P2X7 receptor activation is also known to 
kill intracellular Chlamydia spp., and has also been implicated in the immune response 
to Leishmania spp. 
 
The hypothesis for this PhD project was that activation of the P2X7 receptor results in 
the killing of intracellular T. gondii. Furthermore, that a defective P2X7 receptor gene 
interferes with the normal immune response to T. gondii, rendering an individual more 
susceptible to severe disease following infection with T. gondii. Therefore the specific 
aims for this PhD project were to: 
1. Develop fast, reliable methods to assess the viability and replication of 
intracellular T. gondii tachyzoites in vitro; 
2. Assess the effect of ATP stimulation of human and murine immune cells on the 
viability and/or replication of Type I (RH) tachyzoites of T. gondii; 
3. Assess the effect of deficiencies in P2X7 receptor activity on the ability of ATP 
to affect the viability and/or replication of Type I (RH) tachyzoites of T. gondii; 
4. Assess the effect of deficiencies in P2X7 receptor activity on the production of 
inflammatory cytokines and mediators in response to infection with Type I (RH) 
tachyzoites of T. gondii. 
 
Prior to investigating the role of the P2X7 receptor in the immune response to T. gondii, 
two assays were developed that facilitated the accurate measurement of intracellular T. 
gondii tachyzoite viability or burden/replication. The viability assay used flow 
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cytometry to quickly and accurately quantify intracellular T. gondii tachyzoite viability, 
whereas the burden/replication assay used microplate cytometry to quantify intracellular 
T. gondii tachyzoite burden in host cells available in extremely limited quantities. 
 
The human P2X7 receptor was first investigated through in vitro experiments aimed at 
elucidating a role for P2X7 receptor activation in the human immune response to T. 
gondii. Initially, RH T. gondii strain tachyzoites were infected into monocyte-derived 
macrophages cultured from a donor with full P2X7 receptor function. ATP treatment of 
these cells to activate the receptor significantly reduced the viability of intracellular RH 
T. gondii (measured by the flow cytometry assay) and also reduced the number of 
intracellular YFP expressing RH T. gondii (measured by the microplate cytometry 
assay). Monocyte-derived macrophages from subjects with wild-type and polymorphic 
P2X7 receptor genes were then infected with YFP expressing RH T. gondii, treated with 
ATP and parasite numbers monitored by microplate cytometry. Cells from donors with 
a polymorphism resulting in a loss of P2X7 receptor function were unable to reduce the 
number of intracellular parasites whereas cells from donors with a wild type gene or a 
polymorphism that did not result in a loss of P2X7 receptor function were able to reduce 
intracellular parasite numbers after ATP treatment 
 
To complement the human investigation, experiments involving the murine P2X7 
receptor began with an in vitro investigation into the role of P2X7 receptor activation in 
the murine immune response to T. gondii. These experiments definitively confirmed 
that ATP induced killing of RH T. gondii occurs via P2X7 receptor activation, and not 
any other purinergic receptor/effect of ATP treatment. Blocking activation of the P2X7 
receptor in the immortalised RAW 264.7 mouse macrophage-like cell line by pre-
treatment with the P2X7 receptor antagonist, oATP, showed a reduction in ATP-induced 
RH T. gondii killing. Similarly, ATP treatment of bone marrow-derived macrophages 
cultured from P2X7 receptor knockout mice did not result in a significant reduction in 
intracellular RH T. gondii viability.  
 
The murine P2X7 receptor investigation concluded with in vivo experiments aimed at 
understanding the phenotype of RH T. gondii infection in P2X7 receptor knockout mice. 
These experiments showed that lack of P2X7 receptor expression was associated with 
lower parasite burden at the site of infection and decreased serum concentration of 
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cytokines responsible for promotion and regulation of the inflammatory immune 
response. 
 
The experiments conducted throughout this PhD have aided in the understanding of the 
immune response to T. gondii. It was previously known that P2X7 receptor activation 
was important in the immune response to Mycobacterium spp., Chlamydia spp. and 
Leishmania spp. The role of the P2X7 receptor may now also be extended to include T. 
gondii. 
